Tafenoquine following G6PD screening versus primaquine for the treatment of vivax malaria in Brazil: A cost-effectiveness analysis using a transmission model.
<h4>Background</h4>Malaria transmission modelling has demonstrated the potential impact of semiquantitative glucose-6-phosphate dehydrogenase (G6PD) testing and treatment with single-dose tafenoquine for Plasmodium vivax radical cure but has not investigated the associated costs. This st...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2024-01-01
|
| Series: | PLoS Medicine |
| Online Access: | https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1004255&type=printable |
| _version_ | 1826937193767108608 |
|---|---|
| author | David J Price Narimane Nekkab Wuelton M Monteiro Daniel A M Villela Julie A Simpson Marcus V G Lacerda Michael T White Angela Devine |
| author_facet | David J Price Narimane Nekkab Wuelton M Monteiro Daniel A M Villela Julie A Simpson Marcus V G Lacerda Michael T White Angela Devine |
| author_sort | David J Price |
| collection | DOAJ |
| description | <h4>Background</h4>Malaria transmission modelling has demonstrated the potential impact of semiquantitative glucose-6-phosphate dehydrogenase (G6PD) testing and treatment with single-dose tafenoquine for Plasmodium vivax radical cure but has not investigated the associated costs. This study evaluated the cost-effectiveness of P. vivax treatment with tafenoquine after G6PD testing using a transmission model.<h4>Methods and findings</h4>We explored the cost-effectiveness of using tafenoquine after G6PD screening as compared to usual practice (7-day low-dose primaquine (0.5 mg/kg/day) without G6PD screening) in Brazil using a 10-year time horizon with 5% discounting considering 4 scenarios: (1) tafenoquine for adults only assuming 66.7% primaquine treatment adherence; (2) tafenoquine for adults and children aged >2 years assuming 66.7% primaquine adherence; (3) tafenoquine for adults only assuming 90% primaquine adherence; and (4) tafenoquine for adults only assuming 30% primaquine adherence. The incremental cost-effectiveness ratios (ICERs) were estimated by dividing the incremental costs by the disability-adjusted life years (DALYs) averted. These were compared to a willingness to pay (WTP) threshold of US$7,800 for Brazil, and one-way and probabilistic sensitivity analyses were performed. All 4 scenarios were cost-effective in the base case analysis using this WTP threshold with ICERs ranging from US$154 to US$1,836. One-way sensitivity analyses showed that the results were most sensitive to severity and mortality due to vivax malaria, the lifetime and number of semiquantitative G6PD analysers needed, cost per malaria episode and per G6PD test strips, and life expectancy. All scenarios had a 100% likelihood of being cost-effective at the WTP threshold. The main limitations of this study are due to parameter uncertainty around our cost estimates for low transmission settings, the costs of G6PD screening, and the severity of vivax malaria.<h4>Conclusions</h4>In our modelling study that incorporated impact on transmission, tafenoquine prescribed after a semiquantitative G6PD testing was highly likely to be cost-effective in Brazil. These results demonstrate the potential health and economic importance of ensuring safe and effective radical cure. |
| first_indexed | 2024-03-08T03:11:19Z |
| format | Article |
| id | doaj.art-f2e00a5e586a415a95fa4161f602abd0 |
| institution | Directory Open Access Journal |
| issn | 1549-1277 1549-1676 |
| language | English |
| last_indexed | 2025-02-17T18:35:21Z |
| publishDate | 2024-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Medicine |
| spelling | doaj.art-f2e00a5e586a415a95fa4161f602abd02024-12-12T05:30:52ZengPublic Library of Science (PLoS)PLoS Medicine1549-12771549-16762024-01-01211e100425510.1371/journal.pmed.1004255Tafenoquine following G6PD screening versus primaquine for the treatment of vivax malaria in Brazil: A cost-effectiveness analysis using a transmission model.David J PriceNarimane NekkabWuelton M MonteiroDaniel A M VillelaJulie A SimpsonMarcus V G LacerdaMichael T WhiteAngela Devine<h4>Background</h4>Malaria transmission modelling has demonstrated the potential impact of semiquantitative glucose-6-phosphate dehydrogenase (G6PD) testing and treatment with single-dose tafenoquine for Plasmodium vivax radical cure but has not investigated the associated costs. This study evaluated the cost-effectiveness of P. vivax treatment with tafenoquine after G6PD testing using a transmission model.<h4>Methods and findings</h4>We explored the cost-effectiveness of using tafenoquine after G6PD screening as compared to usual practice (7-day low-dose primaquine (0.5 mg/kg/day) without G6PD screening) in Brazil using a 10-year time horizon with 5% discounting considering 4 scenarios: (1) tafenoquine for adults only assuming 66.7% primaquine treatment adherence; (2) tafenoquine for adults and children aged >2 years assuming 66.7% primaquine adherence; (3) tafenoquine for adults only assuming 90% primaquine adherence; and (4) tafenoquine for adults only assuming 30% primaquine adherence. The incremental cost-effectiveness ratios (ICERs) were estimated by dividing the incremental costs by the disability-adjusted life years (DALYs) averted. These were compared to a willingness to pay (WTP) threshold of US$7,800 for Brazil, and one-way and probabilistic sensitivity analyses were performed. All 4 scenarios were cost-effective in the base case analysis using this WTP threshold with ICERs ranging from US$154 to US$1,836. One-way sensitivity analyses showed that the results were most sensitive to severity and mortality due to vivax malaria, the lifetime and number of semiquantitative G6PD analysers needed, cost per malaria episode and per G6PD test strips, and life expectancy. All scenarios had a 100% likelihood of being cost-effective at the WTP threshold. The main limitations of this study are due to parameter uncertainty around our cost estimates for low transmission settings, the costs of G6PD screening, and the severity of vivax malaria.<h4>Conclusions</h4>In our modelling study that incorporated impact on transmission, tafenoquine prescribed after a semiquantitative G6PD testing was highly likely to be cost-effective in Brazil. These results demonstrate the potential health and economic importance of ensuring safe and effective radical cure.https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1004255&type=printable |
| spellingShingle | David J Price Narimane Nekkab Wuelton M Monteiro Daniel A M Villela Julie A Simpson Marcus V G Lacerda Michael T White Angela Devine Tafenoquine following G6PD screening versus primaquine for the treatment of vivax malaria in Brazil: A cost-effectiveness analysis using a transmission model. PLoS Medicine |
| title | Tafenoquine following G6PD screening versus primaquine for the treatment of vivax malaria in Brazil: A cost-effectiveness analysis using a transmission model. |
| title_full | Tafenoquine following G6PD screening versus primaquine for the treatment of vivax malaria in Brazil: A cost-effectiveness analysis using a transmission model. |
| title_fullStr | Tafenoquine following G6PD screening versus primaquine for the treatment of vivax malaria in Brazil: A cost-effectiveness analysis using a transmission model. |
| title_full_unstemmed | Tafenoquine following G6PD screening versus primaquine for the treatment of vivax malaria in Brazil: A cost-effectiveness analysis using a transmission model. |
| title_short | Tafenoquine following G6PD screening versus primaquine for the treatment of vivax malaria in Brazil: A cost-effectiveness analysis using a transmission model. |
| title_sort | tafenoquine following g6pd screening versus primaquine for the treatment of vivax malaria in brazil a cost effectiveness analysis using a transmission model |
| url | https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1004255&type=printable |
| work_keys_str_mv | AT davidjprice tafenoquinefollowingg6pdscreeningversusprimaquineforthetreatmentofvivaxmalariainbrazilacosteffectivenessanalysisusingatransmissionmodel AT narimanenekkab tafenoquinefollowingg6pdscreeningversusprimaquineforthetreatmentofvivaxmalariainbrazilacosteffectivenessanalysisusingatransmissionmodel AT wueltonmmonteiro tafenoquinefollowingg6pdscreeningversusprimaquineforthetreatmentofvivaxmalariainbrazilacosteffectivenessanalysisusingatransmissionmodel AT danielamvillela tafenoquinefollowingg6pdscreeningversusprimaquineforthetreatmentofvivaxmalariainbrazilacosteffectivenessanalysisusingatransmissionmodel AT julieasimpson tafenoquinefollowingg6pdscreeningversusprimaquineforthetreatmentofvivaxmalariainbrazilacosteffectivenessanalysisusingatransmissionmodel AT marcusvglacerda tafenoquinefollowingg6pdscreeningversusprimaquineforthetreatmentofvivaxmalariainbrazilacosteffectivenessanalysisusingatransmissionmodel AT michaeltwhite tafenoquinefollowingg6pdscreeningversusprimaquineforthetreatmentofvivaxmalariainbrazilacosteffectivenessanalysisusingatransmissionmodel AT angeladevine tafenoquinefollowingg6pdscreeningversusprimaquineforthetreatmentofvivaxmalariainbrazilacosteffectivenessanalysisusingatransmissionmodel |